Key Findings
- Purpose
To evaluate whether palmitoylethanolamide (PEA), a non-intoxicating lipid mediator related to cannabinoid signaling, could reduce pain hypersensitivity and inflammatory activity in sickle cell disease (SCD). - Population (Model)
Female humanized transgenic HbSS Berkeley (BERK) mice, a widely used model that replicates many clinical features of SCD — including chronic pain, acute pain episodes, and organ damage — were treated with oral Levagen+ for 14 days and compared with vehicle-treated controls.
- Headline Result
Levagen+ significantly increased circulating PEA levels and reduced mechanical, cold, and musculoskeletal hyperalgesia. Improvements were observed within one hour of treatment and continued during the 14-day dosing period. The intervention also ameliorated hypoxia-reoxygenation–induced acute hyperalgesia, improved red blood cell counts (~40%) and hemoglobin (~37%), and reduced liver enlargement. - Why It Matters
Pain in SCD is often managed with opioids and other supportive therapies. This study suggests that targeting neuroimmune pathways — particularly mast cell activation and inflammatory signaling — may offer a novel non-opioid approach to chronic SCD pain management. Levagen+ also reduced circulating inflammatory markers including ubstance P, serum amyloid P, and interleukin-6, supporting a mechanistic link between neurogenic inflammation and pain in SCD. - Evidence Gaps & Limitations
The findings are preclinical and limited to a mouse model. Human clinical trials will be required to determine safety, dosing, and clinical efficacy of PEA-based therapies in patients with SCD.
Source: Journal of Sickle Cell Disease- “Levagen+ Ameliorates Hyperalgesia in a Mouse Model of Sickle Cell Disease”
Regulatory & Guideline Watch
Current American Society of Hematology (ASH) guidance emphasizes multimodal pain management in sickle cell disease, with growing interest in therapies that target inflammation, neuroimmune signaling, and disease-specific pain pathways. Translational research such as this study may help expand future non-opioid therapeutic options for chronic SCD pain.